Top 10 Railroad Stocks To Own Right Now

Top 10 Railroad Stocks To Own Right Now: Dendreon Corporation(DNDN)

Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of therapeutics to enhance cancer treatment options for patients. The company offers active cellular immunotherapy and small molecule product candidates to treat various cancers. Its product candidates comprise Provenge (sipuleucel-T), an active cellular immunotherapy for the treatment of metastatic, castrate-resistant prostate cancer; DN24-02, an investigational active immunotherapy for the treatment of patients with bladder, breast, ovarian, and other solid tumors expressing HER2/neu; and TRPM8, a small molecule agonist to transient receptor potential ion channel, for multiple cancers. The company also has a range of products in preclinical studies, which include Carcinoembryonic antigen for the treatment of lung, colon, and breast cancer; and Carbonic AnhydraseIX for the treatment of kidney cancer. Dendreon Corporation was founded in 1992 and is headquartered in S eattle, Washington.

Advisors' Opinion:

• [By John Udovich]

  On Tuesday, small cap biopharmaceutical company Epizyme Inc (NASDAQ: EPZM) surged 75.56% after the company announced that itsEPZ-5676, a DOT1L inhibitor for acute leukemias, had reached its proof-of-concept milestone, meaning its worth taking a closer look at the stock as well as look at the share performance of cancer stocks like large cap Celgene Corporation (NASDAQ: CELG) and small capsDendreon Corporation (NASDAQ: DNDN) and Geron Corporation (NASDAQ: GERN).

• [By Sean Williams]

  Not to sound like a broken record, but Dendreon (NASDAQ: DNDN  ) shareholders received some much-awaited positive news, and they have the EMA's panel to thank. The CHMP recommended that Dendreon's cellular immunotherapy treatment Provenge be approved in the EU for the treatment of metastatic castration-resistant prostate cancer. Dendreon has been bleed! ing money because of Provenge's high price tag in the U.S., which caused insurers to shy away from covering the three-course treatment, and from increased competition. It remains to be seen if this will be too little, too late for Dendreon, but it's nonetheless a big stepping stone toward an expected EU approval.

• [By Sean Williams]

  This week's winner
  Although there was no company-specific news out ofDendreon (NASDAQ: DNDN  ) this week, following weeks of poor performance, it tacked on 8.7%. Presentations at the American Society of Clinical Oncology's annual meeting two weeks ago certainly helped to excite investors with regard to the potential of immunotherapy stocks, but Dendreon needs a lot more help than what a few early and mid-stage studies can offer. If Dendreon is to keep this rally going, it'll need decisively positive data on advanced prostate cancer treatment Provenge in Europe. We should certainly know more about its progress in Europe within the next few months.

source from Top Stocks To Buy For 2015:http://www.topstocksforum.com/top-10-railroad-stocks-to-own-right-now-3.html